LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls
4th Jan 2024 16:54
(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data. Read More
(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data. Read More
(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services. Read More
(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China. Read More
(Alliance News) - Angle PLC has hit a "landmark achievement", says Berenberg, as its pilot study partnership with Eisai Inc may lead to major market expansion. Read More
Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Launches its Portrait Plus CTC staining kit at the San Antonio Breast Cancer Symposium, following "extensive" development, optimisation and validation of the kit. Explains that the kit is read-to-use, and designed for the dentification, characterisation and enumeration of epithelial and mesenchymal cancer cells. This includes those undergoing epithelial-to-mesenchymal transition. Read More
(Alliance News) - Angle PLC on Thursday said it expects revenue in 2023 to more than double from 2022 as it announced the launch of a new test aimed to support cancer therapy studies. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Angle PLC on Tuesday touted the publication of a study by researchers at the University of Tubingen in Germany, which showed that its Parsortix system outperformed the current laboratory standard for disseminated tumour cell harvest. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - Angle PLC on Monday announced the launch of its new Portrait Flex circulating tumour cell assay, which it said will provide valuable trial data and help advance "personalised cancer care." Read More
Angle PLC - Guildford, England-based liquid biopsy company - Hires Brett Swansiger as chief commercial officer and Karen Miller as chief scientific officer. Says Swansiger has over 20 years of experience within the molecular diagnostic and pharmaceutical industries. Most recently, he was COO at DxTerity Diagnostics, a biotechnology company based in the US. Says Miller brings a strong network of relationships within the pharmaceutical and companion diagnostic industries, having over 30 years of experience. She was most recently the CSO at Ixaka, a cell & gene therapy company. Start dates for both roles are undisclosed. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Announces new contract with clinical-stage biotechnology company Artios Pharma for use of two DNA damage response assays in a Phase 1 clinical trial. Artios was Angle's first bespoke assay development customer, selecting it to develop immunofluorescence assays to detect biomarkers on tumour cells. The Phase 1 trial will begin "shortly" with completion expected around the end of 2024. Angle says the assays could later be used in larger and later-stage clinical trials. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Chair Garth Selvey plans to retire from the board after interim results are released in September. Selvey has been chair since 2007. he will hand over the position of chair with immediate effect to Jan Groen, who is currently an independent non-executive director. Groen is also currently the chief executive officer and chair of Intravacc BV. Read More